Infinity Pharmaceuticals, Inc. Announces Global Strategic Alliance With Purdue Pharmaceuticals L.P. and Mundipharma International Limited Encompassing Infinity's Early Clinical and Discovery Programs; Infinity to Receive Up to $75M Equity Investment, Access to $50M Line of Credit, and Significant R&D Funding Over Multiple Years
11/20/2008 8:50:59 AM
CAMBRIDGE, Mass., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has entered into a global strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited, focused on the research, development, and commercialization of Infinity's early clinical and discovery programs, including IPI-926, Infinity's novel inhibitor of the Hedgehog signaling pathway. Infinity expects that this alliance will enable it to aggressively pursue its goal of developing and commercializing its pipeline of innovative anti-cancer agents.
comments powered by